Status:
COMPLETED
A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation
Lead Sponsor:
AbbVie
Conditions:
Chronic Lymphocytic Leukemia (CLL)
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study seeks to assess the effectiveness and safety of venetoclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across clinical practice in th...
Eligibility Criteria
Inclusion
- Has a confirmed diagnosis of relapsed or refractory CLL.
- Patient for whom the physician has decided to initiate CLL treatment with venetoclax (mono and combo therapy), or up to 4 weeks after venetoclax treatment initiation
- Patient voluntarily agrees to participate in this study and signs informed consent form
Exclusion
- Has contraindications to venetoclax as listed on the approved local label in Russian Federation.
- Has Richter syndrome
- Participated in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation
Key Trial Info
Start Date :
February 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 12 2022
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT03873857
Start Date
February 25 2019
End Date
September 12 2022
Last Update
September 1 2023
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Dispensary #2 /ID# 215831
Sochi, Krasnodarskiy Kray, Russia, 354057
2
Moscow State budget healthcare /ID# 212875
Moscow, Moscow, Russia, 125284
3
Moscow Regional Research and Clinical Institute n.a. Vladimirskiy (MONIKI) /ID# 215830
Moscow, Moscow Oblast, Russia, 129110
4
Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 212368
Saint Petersburg, Sankt-Peterburg, Russia, 197101